[go: up one dir, main page]

MX2022004283A - Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. - Google Patents

Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Info

Publication number
MX2022004283A
MX2022004283A MX2022004283A MX2022004283A MX2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A MX 2022004283 A MX2022004283 A MX 2022004283A
Authority
MX
Mexico
Prior art keywords
oxetan
pent
pyrazolo
piperidine
phenoxy
Prior art date
Application number
MX2022004283A
Other languages
English (en)
Inventor
Ann Neale
Dolca Thomas
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022004283A publication Critical patent/MX2022004283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente memoria se describen métodos para tratar pénfigo en un paciente humano que lo necesita que comprenden administrar al paciente humano una dosis de al menos 400 mg de (R)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo (PRN1008) una vez al día (QD) o dos veces al día (BID).
MX2022004283A 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo. MX2022004283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913029P 2019-10-09 2019-10-09
US201962942877P 2019-12-03 2019-12-03
PCT/US2020/054809 WO2021072095A1 (en) 2019-10-09 2020-10-08 Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022004283A true MX2022004283A (es) 2022-07-12

Family

ID=73030241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004283A MX2022004283A (es) 2019-10-09 2020-10-08 Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.

Country Status (13)

Country Link
US (2) US20210106583A1 (es)
EP (1) EP4041240A1 (es)
JP (2) JP7784995B2 (es)
KR (1) KR20220079909A (es)
CN (1) CN115190798A (es)
AU (1) AU2020363873A1 (es)
BR (1) BR112022005575A2 (es)
CA (1) CA3153750A1 (es)
CO (1) CO2022005949A2 (es)
IL (1) IL291726A (es)
MX (1) MX2022004283A (es)
TW (1) TW202128172A (es)
WO (1) WO2021072095A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535403A (zh) * 2023-10-25 2025-09-16 美商普林斯匹亞生物製藥公司 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療慢性自發性蕁麻疹

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181567B9 (en) 2012-09-10 2025-09-24 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
ES2846776T3 (es) 2014-12-24 2021-07-29 Principia Biopharma Inc Dosificación específica del sitio de un inhibidor de BTK
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP7331843B2 (ja) * 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤

Also Published As

Publication number Publication date
JP7784995B2 (ja) 2025-12-12
TW202128172A (zh) 2021-08-01
IL291726A (en) 2022-05-01
WO2021072095A1 (en) 2021-04-15
JP2025157438A (ja) 2025-10-15
US20210106583A1 (en) 2021-04-15
CO2022005949A2 (es) 2022-07-29
AU2020363873A1 (en) 2022-04-14
KR20220079909A (ko) 2022-06-14
EP4041240A1 (en) 2022-08-17
BR112022005575A2 (pt) 2022-06-21
CN115190798A (zh) 2022-10-14
CA3153750A1 (en) 2021-04-15
US20230158033A1 (en) 2023-05-25
JP2022552199A (ja) 2022-12-15

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201792214A1 (ru) Соединения замещенного хиназолина
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021026369A2 (pt) Derivados de 2h-indazol e seu uso no tratamento de doenças
CO2022006087A2 (es) Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo
EA201992658A1 (ru) Методы лечения рекуррентной глиобластомы (rgbm)
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MY199779A (en) Pyrrolopyrimidine compound and use thereof
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
WO2021090070A3 (en) Metered dose for disorders in or around the eye
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2022004283A (es) Metodos para tratar penfigo mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)pipera zin-1-il]pent-2-enonitrilo.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos